Hologic, Inc. (NASDAQ:HOLX) Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 13.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,594 shares of the medical equipment provider's stock after selling 11,373 shares during the period. QRG Capital Management Inc.'s holdings in Hologic were worth $4,669,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in HOLX. Venturi Wealth Management LLC raised its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. Smithfield Trust Co lifted its stake in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in shares of Hologic in the 4th quarter valued at about $49,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Activity

In other news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.88% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HOLX. Citigroup lowered their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Stephens lowered their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Morgan Stanley lowered their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Finally, Raymond James Financial reissued an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Hologic currently has an average rating of "Hold" and a consensus price target of $77.42.

Hologic Price Performance

NASDAQ:HOLX traded up $0.51 on Friday, reaching $64.48. 5,564,249 shares of the company's stock traded hands, compared to its average volume of 2,349,728. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The stock has a 50-day simple moving average of $59.29 and a 200-day simple moving average of $64.37. The firm has a market cap of $14.37 billion, a PE ratio of 27.21, a P/E/G ratio of 2.36 and a beta of 0.55. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business's quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm earned $1.03 earnings per share. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.